Form 4: Heron Therapeutics Director Michael Kaseta Acquires Shares and Options

Director Michael Kaseta of Heron Therapeutics acquired 17,950 shares of common stock and 35,900 stock options on January 30, 2025.

Summary

• Michael Kaseta, a director at Heron Therapeutics, acquired 17,950 shares of common stock on January 30, 2025.
• These shares were granted as restricted stock units that will vest in full on January 30, 2026.
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• Kaseta also acquired 35,900 stock options with an exercise price of $1.73 on the same date.
• These stock options vest and become exercisable in 12 equal monthly installments starting one month after the grant date.
• The stock options expire on January 30, 2035.
• Following these transactions, Kaseta beneficially owns 55,829 shares of common stock and 35,900 stock options.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as it shows a director increasing their stake in the company, which is generally seen as a good sign. However, it is a routine filing and does not contain any major news.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The vesting schedule of the restricted stock units and stock options aligns the director's interests with the long-term performance of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It provides transparency into the holdings of company directors.

Comparison to Industry Standards

• The vesting schedule for the restricted stock units, vesting in full after one year, is a common practice in the industry.
• The 10-year term for the stock options is also within the typical range for such grants.
• The exercise price of $1.73 for the stock options is a standard practice, often set at or near the market price at the time of grant.

Stakeholder Impact

• The transaction may have a slightly positive impact on shareholder sentiment as it indicates confidence from a company director.

Key Dates

Keywords

Heron Therapeutics, Michael Kaseta, stock options, restricted stock units, insider trading, beneficial ownership, equity